Sign In
Buy BIOA
$16.04
-0.500 (-3.02%)
At Close: Jun 03, 2026
BioAge Labs to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 20'th Aug 2025
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for m
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
09:00am, Friday, 15'th Aug 2025
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
11:14pm, Wednesday, 06'th Aug 2025
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
04:30pm, Wednesday, 06'th Aug 2025
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of propr
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA)
Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
09:00am, Tuesday, 17'th Jun 2025
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform
BioAge Labs to Present at Upcoming Investor Conferences
04:30pm, Tuesday, 27'th May 2025
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for me
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA)
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
04:30pm, Tuesday, 06'th May 2025
RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic disea
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
04:30pm, Thursday, 20'th Mar 2025
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships wit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. Lawsuit - BIOA
09:45pm, Monday, 10'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities la
Final Deadline for the BioAge Labs, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - BIOA
09:30pm, Monday, 10'th Mar 2025
LOS ANGELES , March 10, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against BioAge Labs, Inc. ("BioAge" or "the Company") (NASDAQ: BIOA) for violations of the
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – BIOA
06:45pm, Monday, 10'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities la
BIOA Deadline Today: BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit
06:33pm, Monday, 10'th Mar 2025
NEW YORK , March 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the re
